國家衛生研究院 NHRI:Item 3990099045/5205
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855554      在线人数 : 1205
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/5205


    题名: Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay
    作者: Yang, CC;Hsieh, YC;Lee, SJ;Wu, SH;Liao, CL;Tsao, CH;Chao, YS;Chern, JH;Wu, CP;Yueh, A
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Dengue virus (DENV) causes disease globally with an estimated 25 to 100 million new infections per year. At present, no effective vaccine is available and treatment is supportive. In this study, we identified a potent and selective small-molecule inhibitor, BP2109, of the DENV NS2B/NS3 protease by high-throughput screening assay using recombinant protease complex consisting of central hydrophilic portion of NS2B and N-terminus of protease domain. BP2109 inhibited DENV (serotype 1-4) but not Japanese encephalitis virus (JEV) replication and viral RNA synthesis without detectable cytotoxicity. The compound inhibited recombinant DENV-2 NS2B/NS3 protease with an IC50 value of 15.43 +/- 2.12 muM and reduced the reporter expression of the DENV-2 replicon with an EC50 value of 0.17 +/- 0.01 muM. Sequencing analyses of several individual clones derived from BP2109-resistant DENV-2 RNAs revealed that two amino acid substitutions (R55K and E80K) are found in the region of NS2B, a cofactor of NS2B/NS3 protease complex. The introduction of R55K and E80K double mutations into the dengue NS2B/NS3 protease and a dengue replicon construct conferred 10.3- and 73.8-fold resistance to BP2109, respectively. The E80K mutation was further determined as the key mutation conferring dengue replicon drug resistance (61.3-fold) to BP2109, whereas the R55K mutation alone did not affect drug resistance to BP2109. Both R55K and E80K mutations are located at the central hydrophilic portion of NS2B cofactor where extensive interactions with NS3pro domain exist. Thus, our data provide evidence that BP2109 likely inhibits DENV by a novel mechanism.
    日期: 2011-01
    關聯: Antimicrobial Agents and Chemotherapy. 2011 Jan;55(1):229-238.
    Link to: http://dx.doi.org/10.1128/aac.00855-10
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000285577400028
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=78650636283
    显示于类别:[趙宇生(2002-2013)] 期刊論文
    [岳嶽] 期刊論文
    [李秀珠] 期刊論文
    [陳志豪] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB20937790.pdf709KbAdobe PDF1011检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈